Toxins 2010, 2(9), 2242-2257; doi:10.3390/toxins2092242
Article

SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model

1email, 2email, 2email, 1email and 1,* email
Received: 23 July 2010; in revised form: 20 August 2010 / Accepted: 26 August 2010 / Published: 27 August 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: SLT-VEGF is a recombinant cytotoxin comprised of Shiga-like toxin (SLT) subunit A fused to human vascular endothelial growth factor (VEGF). It is highly cytotoxic to tumor endothelial cells overexpressing VEGF receptor-2 (VEGFR-2/KDR/Flk1) and inhibits the growth of primary tumors in subcutaneous models of breast and prostate cancer and inhibits metastatic dissemination in orthotopic models of pancreatic cancer. We examined the efficacy of SLT-VEGF in limiting tumor growth and metastasis in an orthotopic melanoma model, using NCR athymic nude mice inoculated with highly metastatic Line IV Cl 1 cultured human melanoma cells. Twice weekly injections of SLT-VEGF were started when tumors became palpable at one week after intradermal injection of 1 × 106 cells/mouse. Despite selective depletion of VEGFR-2 overexpressing endothelial cells from the tumor vasculature, SLT-VEGF treatment did not affect tumor growth. However, after primary tumors were removed, continued SLT-VEGF treatment led to fewer tumor recurrences (p = 0.007), reduced the incidence of lung metastasis (p = 0.038), and improved survival (p = 0.002). These results suggest that SLT-VEGF is effective at the very early stages of tumor development, when selective killing of VEGFR-2 overexpressing endothelial cells can still prevent further progression. We hypothesize that SLT-VEGF could be a promising adjuvant therapy to inhibit or prevent outgrowth of metastatic foci after excision of aggressive primary melanoma lesions.
Keywords: biological therapeutics; shiga-like toxin; SLT-VEGF; melanoma; angiogenesis; metastasis; VEGF receptor targeting
PDF Full-text Download PDF Full-Text [873 KB, uploaded 27 August 2010 14:53 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Ackerman, R.; Backer, J.M.; Backer, M.; Skariah, S.; Hamby, C.V. SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model. Toxins 2010, 2, 2242-2257.

AMA Style

Ackerman R, Backer JM, Backer M, Skariah S, Hamby CV. SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model. Toxins. 2010; 2(9):2242-2257.

Chicago/Turabian Style

Ackerman, Rachel; Backer, Joseph M.; Backer, Marina; Skariah, Sini; Hamby, Carl V. 2010. "SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model." Toxins 2, no. 9: 2242-2257.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert